Literature DB >> 26890156

Infection-related and -unrelated malignancies, HIV and the aging population.

L Shepherd1, Áh Borges2, B Ledergerber3, P Domingo4, A Castagna5, J Rockstroh6, B Knysz7, J Tomazic8, I Karpov9, O Kirk2, J Lundgren2, A Mocroft1.   

Abstract

OBJECTIVES: HIV-positive people have increased risk of infection-related malignancies (IRMs) and infection-unrelated malignancies (IURMs). The aim of the study was to determine the impact of aging on future IRM and IURM incidence.
METHODS: People enrolled in EuroSIDA and followed from the latest of the first visit or 1 January 2001 until the last visit or death were included in the study. Poisson regression was used to investigate the impact of aging on the incidence of IRMs and IURMs, adjusting for demographic, clinical and laboratory confounders. Linear exponential smoothing models forecasted future incidence.
RESULTS: A total of 15 648 people contributed 95 033 person-years of follow-up, of whom 610 developed 643 malignancies [IRMs: 388 (60%); IURMs: 255 (40%)]. After adjustment, a higher IRM incidence was associated with a lower CD4 count [adjusted incidence rate ratio (aIRR) CD4 count < 200 cells/μL: 3.77; 95% confidence interval (CI) 2.59, 5.51; compared with ≥ 500 cells/μL], independent of age, while a CD4 count < 200 cells/μL was associated with IURMs in people aged < 50 years only (aIRR: 2.51; 95% CI 1.40-4.54). Smoking was associated with IURMs (aIRR: 1.75; 95% CI 1.23, 2.49) compared with never smokers in people aged ≥ 50 years only, and not with IRMs. The incidences of both IURMs and IRMs increased with older age. It was projected that the incidence of IRMs would decrease by 29% over a 5-year period from 3.1 (95% CI 1.5-5.9) per 1000 person-years in 2011, whereas the IURM incidence would increase by 44% from 4.1 (95% CI 2.2-7.2) per 1000 person-years over the same period.
CONCLUSIONS: Demographic and HIV-related risk factors for IURMs (aging and smoking) and IRMs (immunodeficiency and ongoing viral replication) differ markedly and the contribution from IURMs relative to IRMs will continue to increase as a result of aging of the HIV-infected population, high smoking and lung cancer prevalence and a low prevalence of untreated HIV infection. These findings suggest the need for targeted preventive measures and evaluation of the cost-benefit of screening for IURMs in HIV-infected populations.
© 2016 British HIV Association.

Entities:  

Keywords:  HIV; aging; malignancies; virus-associated malignancies

Mesh:

Year:  2016        PMID: 26890156     DOI: 10.1111/hiv.12359

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  12 in total

Review 1.  Managing HIV infection in patients older than 50 years.

Authors:  Jacqueline M McMillan; Hartmut Krentz; M John Gill; David B Hogan
Journal:  CMAJ       Date:  2018-10-22       Impact factor: 8.262

2.  Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

Authors:  Álvaro H Borges; Jacqueline Neuhaus; Abdel G Babiker; Keith Henry; Mamta K Jain; Adrian Palfreeman; Peter Mugyenyi; Pere Domingo; Christian Hoffmann; Tim R H Read; Sanjay Pujari; Michael Meulbroek; Margaret Johnson; Timothy Wilkin; Ronald Mitsuyasu
Journal:  Clin Infect Dis       Date:  2016-09-08       Impact factor: 9.079

Review 3.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

4.  Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis.

Authors:  Pietro Mazzuca; Stefania Marsico; Kai Schulze; Stefania Mitola; Marina C Pils; Cinzia Giagulli; Carlos A Guzman; Arnaldo Caruso; Francesca Caccuri
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 5.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

Review 6.  The effect of non-AIDS-defining cancers on people living with HIV.

Authors:  Elizabeth Y Chiao; Anna Coghill; Darya Kizub; Valeria Fink; Ntokozo Ndlovu; Angela Mazul; Keith Sigel
Journal:  Lancet Oncol       Date:  2021-06       Impact factor: 54.433

Review 7.  A Review of Management of Inflammation in the HIV Population.

Authors:  Jihad Slim; Christopher F Saling
Journal:  Biomed Res Int       Date:  2016-09-27       Impact factor: 3.411

Review 8.  Recent advances in cancer outcomes in HIV-positive smokers.

Authors:  Sabina Ranjit; Santosh Kumar
Journal:  F1000Res       Date:  2018-06-11

Review 9.  Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?

Authors:  Michelle L Giles; Coral Gartner; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2018-12-12       Impact factor: 2.250

10.  Profile of elderly patients receiving antiretroviral therapy at Newlands Clinic in 2020: A cross-sectional study.

Authors:  Cleophas Chimbetete; Tinashe Mudzviti; Tinei Shamu
Journal:  South Afr J HIV Med       Date:  2020-12-10       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.